Phathom Pharmaceuticals Gains FDA Approval for VOQUEZNA® Exclusivity

Phathom Pharmaceuticals ( (PHAT) ) has provided an announcement.

On June 6, 2025, Phathom Pharmaceuticals announced that the FDA approved their Citizen Petition, filed in December 2024, to correct the Orange Book and recognize a 10-year New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032. This approval enhances Phathom’s market position by securing extended exclusivity for their product, potentially impacting their commercialization strategy and competitive landscape in the gastrointestinal treatment market.

The most recent analyst rating on (PHAT) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Phathom Pharmaceuticals stock, see the PHAT Stock Forecast page.

Spark’s Take on PHAT Stock

According to Spark, TipRanks’ AI Analyst, PHAT is a Neutral.

Phathom Pharmaceuticals is in a challenging financial position, with substantial net losses and reliance on external financing being key concerns. However, the company’s strategic focus on cost management and VOQUEZNA’s commercial success offer some positive prospects. Technical indicators suggest potential short-term momentum, though high volatility remains a risk. New board appointments may strengthen governance but do not offset financial concerns.

To see Spark’s full report on PHAT stock, click here.

More about Phathom Pharmaceuticals

Phathom Pharmaceuticals is a company in the pharmaceutical industry, primarily focused on developing and commercializing novel treatments for gastrointestinal diseases. Their market focus includes products like VOQUEZNA® (vonoprazan) tablets, which are designed to address unmet medical needs in this therapeutic area.

Average Trading Volume: 1,629,566

Technical Sentiment Signal: Sell

Current Market Cap: $328.1M

Learn more about PHAT stock on TipRanks’ Stock Analysis page.